← Back to home

Hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-tma)

Clinical trials for Hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-tma) explained in plain language.

Never miss a new study

Get alerted when new Hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-tma) trials appear

Sign up with your email to follow new studies for Hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-tma), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Experimental drug offered to stem cell transplant patients with rare blood disorder

Disease control Approved

This program provides narsoplimab, an experimental drug, to patients who develop a serious blood clotting condition called thrombotic microangiopathy after a stem cell transplant. The goal is to offer treatment when no other options are available. Patients must have had a stem ce…

Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)

Sponsor: Omeros Corporation • Aim: Disease control

Last updated Jun 27, 2026 09:10 UTC

Hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-tma)

Get alerted when new Hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-tma) trials appear

Experimental drug offered to stem cell transplant patients with rare blood disorder